Sanuwave Projects Q1 Revenue of $9.6–$9.7M, Up 3–4% Year-Over-Year
Sanuwave Health expects Q1 2026 revenue of $9.6–$9.7 million, marking a 3–4% increase year-over-year and aligning with prior guidance. Management cited timing shifts in large deals and reimbursement adjustments in wound care as headwinds, while robust conference engagement underscores growing clinician interest in its Ultramist platform.
1. Preliminary Q1 Revenue Highlights
Sanuwave Health expects Q1 2026 revenue of $9.6–$9.7 million, representing 3–4% year-over-year growth and fitting within the guidance range provided after Q4 2025 earnings.
2. Deal Timing and Reimbursement Impact
Several sizeable deals shifted into Q2, leading revenue to the lower end of guidance, while recent changes in skin substitute and allograft reimbursement prompted a temporary pullback from some wound care practitioners.
3. Strong Conference Engagement
At the SAWC conference in Charlotte, Sanuwave’s booth saw record attendance, hands-on workshops filled to capacity and high interest from practitioners exploring Ultramist as a wound care solution.
4. Management Outlook and Next Steps
Management remains optimistic about market recovery and plans to lean into educational initiatives, with final Q1 financial results to be released in May.